VirEOS

A research consortium under the “Excellence of Science” (EOS) initiative, uniting Belgian experts in virology and molecular interactions.

We investigate various aspects of SARS-CoV-2 infection, from host pathogenesis to detailed molecular mechanisms of cell infection by the virus.

We also develop vaccines and antiviral molecules to combat SARS-CoV-2 and related viruses that could emerge.

VirEOS research project

VirEOS : Preparedness to viral pandemics

Advancing our understanding of SARS coronavirus antigenic and pathogenic evolution:

A major concern is the emergence of SARS-CoV-2 variants, which are less susceptible to infection- and vaccine-induced immunity. Next to this uncertainty on how the virus will continue to evolve, the very high patient-to-patient variability in disease severity upon SARS-CoV-2 infection is poorly understood. In this project, we will tackle these two key aspects to anticipate on SARS-CoV-2 evolution and guide future therapies for those patients that are most at risk. In addition, fundamental aspects of coronavirus infection will be studied to prepare a specific response against infections by these viruses.

Research highlight

Single-Molecule Investigation of the Binding Interface Stability of SARS-CoV-2 Variants with ACE2

A major issue concerning COVID-19 is the sustainability of the immune response generated after infection or after vaccination.

In a research conducted by two teams of the VirEOS project, single-molecule force spectroscopy was used to analyse the interaction strength of spike variants with the Ace2 receptor. This study suggests that vaccination before infection may provide stronger protection across variants.

Ankita Ray, Thu Thi Minh Tran, Rita dos Santos Natividade, Rodrigo A. Moreira, Joshua D. Simpson, Danahe Mohammed, Melanie Koehler, Simon J. L Petitjean, Qingrong Zhang, Fabrice Bureau, Laurent Gillet, Adolfo B. Poma, and David Alsteens ACS Nanoscience Au 2024 4 (2), 136-145 DOI: 10.1021/acsnanoscienceau.3c00060